ARTICLE | Finance
With Rivus’ first-in-class obesity therapy in clinic, RA leads $132M series B
Virginia-based start-up has begun Phase IIa heart failure study, is planning Phase IIb trial in obesity that will include diabetic patients
September 22, 2022 9:44 PM UTC
With its new $132 million round, Rivus will continue clinical testing of a lead candidate that it believes represents a differentiated approach to treating not only obesity-related disorders, but also obesity itself.
Early Thursday, Rivus Pharmaceuticals Inc. said RA Capital Management led a series B round alongside new and existing investors. The funding builds on a $35 million series A round announced in July 2021, when the company emerged from stealth mode...
BCIQ Company Profiles